Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Part of paid clinical trials in San Francisco, California.

Sponsor
Zenith Epigenetics
Study ID
NCT04145375
Phase
PHASE1/PHASE2
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ZEN003694 — DRUG
    Up to 120mg
  • Enzalutamide — DRUG
    160mg

Study Details

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Key Dates

Start date
Nov 12, 2019
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: ZEN003694 in Combination with Enzalutamide
    Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide

Primary Outcome Measure

Incidence of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE) [ Time Frame: Up to 3 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of California San Francisco Medical CenterSan FranciscoCalifornia94104-
Oregon Health & Science UniversityPortlandOregon97239-

Find similar trials in San Francisco, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University of California San Francisco Medical Center· San Francisco, CAOregon Health & Science University· Portland, OR

Related Studies